A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic Cancer

Trial Profile

A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PAN-01
  • Most Recent Events

    • 07 Jun 2016 Primary endpoint has not been met. (Overall survival), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2015 The follow-up phase is ongoing and a final analysis will be conducted in July 2015, according to the ASCO 2015 abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top